Evidence map›Paper›PMID 39161336›Full record

ReviewOncology letters2024

Sarcomatoid carcinoma of the pancreas (Review).

Yijie Ma, Yiwen Yang, Huizhi Zhang, Joseph Mugaanyi, Yangke Hu, Shengdong Wu, Caide Lu, Shuqi Mao, Ke Wang

Abstract readReview
In one paragraph

Review in Oncology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yijie MaDepartment of Hepatobiliary Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315048, P.R. China.
Yiwen YangDepartment of Hepatobiliary Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315048, P.R. China.
Huizhi ZhangDepartment of Hepatobiliary Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315048, P.R. China.
Joseph MugaanyiDepartment of Hepatobiliary Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315048, P.R. China.
Yangke HuDepartment of Hepatobiliary Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315048, P.R. China.
Shengdong WuDepartment of Hepatobiliary Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315048, P.R. China.
Caide LuDepartment of Hepatobiliary Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315048, P.R. China.
Shuqi MaoDepartment of Hepatobiliary Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315048, P.R. China.
Ke WangDepartment of Hepatobiliary Pancreatic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang 315048, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcomatoid carcinoma of the pancreas (SCP) is a rare and aggressive subtype of undifferentiated pancreatic ductal adenocarcinoma, with a generally poor prognosis and only sporadic cases reported worldwide. Histologically, the most notable feature of SCP is the presence of abundant of mesenchymatoid spindle tumor cells in the tumor, which lack glandular differentiation. Immunohistochemically, SCP is characterized by the expression of both mesenchymal and epithelial markers. With only a few reported cases, there is limited knowledge about its molecular and clinicopathological characteristics. Therefore, the present study performed a literature search to identify all relevant published studies. The present review provides an overview of the histogenesis, diagnosis, genetic features, prognosis and treatment of SCP, specifically focusing on the molecular alterations. Furthermore, a single-center experience is reported, which adds to the limited evidence available in the literature.

Indexed as

PCprecision oncologySCtumors

Identifiers

PMID39161336
PMCPMC11332573

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.